FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3081849955> ?p ?o ?g. }

• W3081849955 endingPage "10340" @default.
• W3081849955 startingPage "10326" @default.
• W3081849955 abstract "Although dyslipidemia commonly occurs in patients with acute promyelocytic leukemia (APL) in response to anti-APL therapy, the underlying mechanism and the lipid statuses of patients with newly diagnosed APL remain to be addressed. Methods: We conducted a retrospective study to investigate the lipid profiles of APL patients. PML-RARα transgenic mice and APL cells-transplanted mice were used to assess the effects of APL cells on the blood/liver lipid levels. Subsequently, gene set enrichment analysis, western blot and dual luciferase reporter assay were performed to examine the role and mechanism of PML-RARα and TRIB3 in lipid metabolism regulation in APL patients at pretreatment and after induction therapy. Results: APL patients exhibited a higher prevalence of dyslipidemia before anti-APL therapy based on a retrospective study. Furthermore, APL cells caused secretion of triglycerides, cholesterol, and PCSK9 from hepatocytes and degradation of low-density lipoprotein receptors in hepatocytes, which elevated the lipid levels in APL cell-transplanted mice and Pml-Rarα transgenic mice. Mechanistically, pseudokinase TRIB3 interacted with PML-RARα to inhibit PPARγ activity by interfering with the interaction of PPARγ and RXR and promoting PPARγ degradation. Thus, reduced PPARγ activity in APL cells decreased leptin but increased resistin expression, causing lipid metabolism disorder in hepatocytes and subsequent dyslipidemia in mice. Although arsenic/ATRA therapy degraded PML-RARα and restored PPARγ expression, it exacerbated dyslipidemia in APL patients. The elevated TRIB3 expression in response to arsenic/ATRA therapy suppressed PPARγ activity by disrupting the PPARγ/RXR dimer, which resulted in dyslipidemia in APL patients undergoing therapy. Indeed, the PPAR activator not only enhanced the anti-APL effects of arsenic/ATRA by suppressing TRIB3 expression but also reduced therapy-induced dyslipidemia in APL patients. Conclusion: Our work reveals the critical role of the PML-RARα/PPARγ/TRIB3 axis in the development of dyslipidemia in APL patients, potentially conferring a rationale for combining ATRA/arsenic with the PPAR activator for APL treatment." @default.
• W3081849955 created "2020-09-08" @default.
• W3081849955 creator A5017100408 @default.
• W3081849955 creator A5024458968 @default.
• W3081849955 creator A5026824169 @default.
• W3081849955 creator A5056750271 @default.
• W3081849955 creator A5062663651 @default.
• W3081849955 creator A5070812231 @default.
• W3081849955 creator A5087255205 @default.
• W3081849955 creator A5091003916 @default.
• W3081849955 date "2020-01-01" @default.
• W3081849955 modified "2023-09-27" @default.
• W3081849955 title "PML-RARα interaction with TRIB3 impedes PPARγ/RXR function and triggers dyslipidemia in acute promyelocytic leukemia" @default.
• W3081849955 cites W1458331036 @default.
• W3081849955 cites W1481314844 @default.
• W3081849955 cites W1581289874 @default.
• W3081849955 cites W1895931987 @default.
• W3081849955 cites W1904222554 @default.
• W3081849955 cites W1909732837 @default.
• W3081849955 cites W1917585691 @default.
• W3081849955 cites W1966361246 @default.
• W3081849955 cites W1966975625 @default.
• W3081849955 cites W1967680216 @default.
• W3081849955 cites W1990318439 @default.
• W3081849955 cites W1991642946 @default.
• W3081849955 cites W1996840851 @default.
• W3081849955 cites W2000470696 @default.
• W3081849955 cites W2004467408 @default.
• W3081849955 cites W2007381747 @default.
• W3081849955 cites W2019225686 @default.
• W3081849955 cites W2019506693 @default.
• W3081849955 cites W2023392000 @default.
• W3081849955 cites W2037209340 @default.
• W3081849955 cites W2044546177 @default.
• W3081849955 cites W2047870782 @default.
• W3081849955 cites W2049362524 @default.
• W3081849955 cites W2050778114 @default.
• W3081849955 cites W2053747871 @default.
• W3081849955 cites W2058237671 @default.
• W3081849955 cites W2064484411 @default.
• W3081849955 cites W2071845076 @default.
• W3081849955 cites W2091007186 @default.
• W3081849955 cites W2105259330 @default.
• W3081849955 cites W2112188003 @default.
• W3081849955 cites W2114188307 @default.
• W3081849955 cites W2124142587 @default.
• W3081849955 cites W2134847924 @default.
• W3081849955 cites W2141982415 @default.
• W3081849955 cites W2158064069 @default.
• W3081849955 cites W2163810943 @default.
• W3081849955 cites W2474389367 @default.
• W3081849955 cites W2515755955 @default.
• W3081849955 cites W2528246672 @default.
• W3081849955 cites W2612175365 @default.
• W3081849955 cites W2612676865 @default.
• W3081849955 cites W2626760225 @default.
• W3081849955 cites W2768202893 @default.
• W3081849955 cites W2774860131 @default.
• W3081849955 cites W2793187747 @default.
• W3081849955 cites W2805785487 @default.
• W3081849955 cites W2806637980 @default.
• W3081849955 cites W2807061724 @default.
• W3081849955 cites W2809050604 @default.
• W3081849955 cites W2976837897 @default.
• W3081849955 cites W2994263765 @default.
• W3081849955 cites W2254384777 @default.
• W3081849955 doi "https://doi.org/10.7150/thno.45924" @default.
• W3081849955 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7481410" @default.
• W3081849955 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32929351" @default.
• W3081849955 hasPublicationYear "2020" @default.
• W3081849955 type Work @default.
• W3081849955 sameAs 3081849955 @default.
• W3081849955 citedByCount "10" @default.
• W3081849955 countsByYear W30818499552020 @default.
• W3081849955 countsByYear W30818499552021 @default.
• W3081849955 countsByYear W30818499552022 @default.
• W3081849955 countsByYear W30818499552023 @default.
• W3081849955 crossrefType "journal-article" @default.
• W3081849955 hasAuthorship W3081849955A5017100408 @default.
• W3081849955 hasAuthorship W3081849955A5024458968 @default.
• W3081849955 hasAuthorship W3081849955A5026824169 @default.
• W3081849955 hasAuthorship W3081849955A5056750271 @default.
• W3081849955 hasAuthorship W3081849955A5062663651 @default.
• W3081849955 hasAuthorship W3081849955A5070812231 @default.
• W3081849955 hasAuthorship W3081849955A5087255205 @default.
• W3081849955 hasAuthorship W3081849955A5091003916 @default.
• W3081849955 hasBestOaLocation W30818499551 @default.
• W3081849955 hasConcept C111441629 @default.
• W3081849955 hasConcept C126322002 @default.
• W3081849955 hasConcept C14036430 @default.
• W3081849955 hasConcept C170493617 @default.
• W3081849955 hasConcept C185592680 @default.
• W3081849955 hasConcept C187345961 @default.
• W3081849955 hasConcept C2776601000 @default.
• W3081849955 hasConcept C2778096610 @default.
• W3081849955 hasConcept C2778461978 @default.
• W3081849955 hasConcept C2779134260 @default.
• W3081849955 hasConcept C2781121885 @default.

• next